In Vitro vs. In Vivo Potency Assays: Which Approach Is Best for Biopharmaceutical Product Characterization?

In vivo potency assays, by contrast, measure biological effects in living organisms. This can capture complex physiological interactions that cannot always be reproduced in vitro, but it also introduces variability due to differences in animal physiology and experimental conditions.

Manufacturing and Operational Considerations

From an operational perspective, in vitro assays offer several advantages:

• faster turnaround times

• higher throughput testing

• lower costs

• improved reproducibility

These characteristics make them particularly well suited for routine batch release testing in commercial manufacturing.

In vivo assays, however, can require longer experimental timelines, specialized facilities, and careful control of animal welfare protocols. These factors increase both operational complexity and cost.

Regulatory agencies increasingly advocate for reducing or eliminating animal testing when possible. Modern regulatory guidance encourages developers to adopt mechanism-based in vitro potency assays that directly reflect the product’s mode of action.

However, regulators may still require in vivo assays if no validated in vitro test can adequately capture the drug’s biological activity.

In practice, many development programs begin with in vivo assays but transition to in vitro methods as mechanistic understanding improves.

In vitro potency assays are generally preferred when:

• the mechanism of action is well understood

• reliable cell-based models exist

• reproducibility and high-throughput testing are required

In vivo assays may be necessary when:

• the biological mechanism is complex or poorly understood

• no suitable in vitro surrogate exists

• whole-organism responses must be evaluated

For most modern biologics, in vitro potency assays represent the preferred regulatory and operational approach due to their precision, scalability, and ethical advantages.

In vivo assays remain important tools for certain complex biologics but are increasingly viewed as bridging or legacy methods that developers aim to replace with validated in vitro assays whenever possible.